<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634061</url>
  </required_header>
  <id_info>
    <org_study_id>CBEZ235D2101</org_study_id>
    <secondary_id>2012-002250-23</secondary_id>
    <nct_id>NCT01634061</nct_id>
  </id_info>
  <brief_title>Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients</brief_title>
  <official_title>Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study of abiraterone acetate in combination with BEZ235 and abiraterone&#xD;
      acetate in combination with BKM120 in CRPC patients with abiraterone acetate failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dose-escalation part will first determine the maximum tolerated dose (MTD) and/or&#xD;
      recomended dose for expansion (RDE) of abiraterone acetate in combination with BEZ235 and&#xD;
      abiraterone acetate in combination with BKM120 in CRPC patients with abiraterone acetate&#xD;
      failure.&#xD;
&#xD;
      Subsequently, the MTD and/or RDE of each combination will be investigated in two expansion&#xD;
      treatment groups of CRPC patients who have failed abiraterone acetate therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>from days 1-35 in BEZ235/abiraterone acetate arm and from days 1-28 in BKM120/abiraterone acetate arm</time_frame>
    <description>Dose escalation part: Determine MTD and /or RDE of the combinations abiraterone acetate + BEZ235 and abiraterone acetate + BKM120 by assessing the incidence of DLTs in cycle 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate specific antigen (PSA) decline ≥ 30%</measure>
    <time_frame>At week 12 or later after treatment discontinuation</time_frame>
    <description>Dose expansion part: Assess anti-tumor activity of the combinations (abiraterone acetate + BEZ235 and abiraterone acetate + BKM120) in castration-resistant prostate cancer patients with abiraterone acetate failure as on treatment PSA progression according to prostate cancer working group criteria 2 (PCWG2) by assessing PSA decline ≥ 30% at Week 12 or later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with at least one adverse event</measure>
    <time_frame>Treatment start until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiological Progression Free Survival as per RECIST 1.1 and PCWG2</measure>
    <time_frame>Every 12 weeks until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiological Response Rate according to RECIST 1.1</measure>
    <time_frame>Every 12 weeks until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From treatment start until 75% of deaths from any cause have occurred</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of patients with laboratory abnormalities</measure>
    <time_frame>Treatment start until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG (electrocardiogram)</measure>
    <time_frame>Treatment start until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs</measure>
    <time_frame>Treatment start until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mood scales</measure>
    <time_frame>Treatment start until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation: BEZ235 + Zytiga®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation: BKM120 + Zytiga®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion: BEZ235 + Zytiga®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate&#xD;
Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: BKM120 + Zytiga®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235</intervention_name>
    <description>BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.</description>
    <arm_group_label>Dose escalation: BEZ235 + Zytiga®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <description>BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.</description>
    <arm_group_label>Dose escalation: BKM120 + Zytiga®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235</intervention_name>
    <description>BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.</description>
    <arm_group_label>Dose expansion: BEZ235 + Zytiga®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <description>BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.</description>
    <arm_group_label>Dose Expansion: BKM120 + Zytiga®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males ≥ 18 years old&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status ≤ 2&#xD;
&#xD;
          -  Patient must have a castrate level of testosterone (&lt;= 50 ng/dL or 1.7 nmol/L). (&#xD;
             Castrate status must be maintained by continued GnRH analogues unless patient has&#xD;
             undergone surgical orchiectomy).&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of advanced or metastatic prostate&#xD;
             cancer.&#xD;
&#xD;
          -  Advanced or metastatic castration-resistant prostate cancer progression after&#xD;
             abiraterone acetate failure&#xD;
&#xD;
          -  Patients should have no more than 2 lines of prior chemotherapies including cytotoxic&#xD;
             agents&#xD;
&#xD;
          -  Discontinuation of all anti-androgen, anti-neoplastic or investigational treatment &gt;=&#xD;
             4 weeks (6 weeks for bicalutamide).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with PI3K pathway inhibitors (e.g. PI3K, AKT, mTOR inhibitor),&#xD;
             ketoconazole, CYP17 inhibitors (exception of AA), or enzalutamide.&#xD;
&#xD;
          -  Patient has active uncontrolled or symptomatic CNS metastases&#xD;
&#xD;
          -  Inadequately controlled hypertension (e.g. systolic blood pressure &gt;=160 mmHg or&#xD;
             diastolic blood pressure &gt;=95 mmHg)&#xD;
&#xD;
          -  Patient has a QTcF &gt; 480 msec on the screening ECG (using the QTcF formula), has a&#xD;
             short/long QT syndrome, or history of QT prolongation/Torsades de Pointes&#xD;
&#xD;
          -  Patient has impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of study drugs&#xD;
&#xD;
          -  Patient has a medically documented history of or active major depressive episode,&#xD;
             bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of&#xD;
             suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self&#xD;
             or others)&#xD;
&#xD;
          -  Patients who experienced dose reductions and/or treatment interruptions due to&#xD;
             abiraterone acetate related toxicities (i.e. serious AEs, AEs, liver toxicities during&#xD;
             abiraterone acetate treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center SC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Hackensack Univ</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussels</city>
        <zip>BE-B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15047</url>
    <description>Results for CBEZ235D2101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>July 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Castration-resistant prostate cancer, abiraterone acetate, BEZ235, BKM120, dose escalation, abiraterone acetate failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactolisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

